The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept : in the ERASURE study , the rates were 81.6 % with 300 mg of secukinumab , 71.6 % with 150 mg of secukinumab , and 4.5 % with placebo ; in the FIXTURE study , the rates were 77.1 % with 300 mg of secukinumab , 67.0 % with 150 mg of secukinumab , 44.0 % with etanercept , and 4.9 % with placebo ( P < 0.001 for each secukinumab dose vs. comparators ) .